Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE

Quest Diagnostics opens the week with a full earnings calendar and a clear analyst view, as the healthcare diagnostics group prepares for its next quarterly update on the NYSE.

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-29, 09:51.

Quest Diagnostics (US74834L1008) starts the week with attention on its upcoming quarterly earnings schedule and its position in the S&P 500 on the New York Stock Exchange. Consensus expectations for revenue and earnings frame the picture for the diagnostics provider, according to recent analyst data.

What analysts currently expect

Analysts following Quest Diagnostics on Wall Street track the stock as part of the broader US healthcare diagnostics sector, which also includes peers such as Laboratory Corporation of America. Consensus data compiled by MarketScreener shows a mix of Buy and Hold ratings, with a clear majority of analysts seeing the shares fairly valued in the current range, based on their published research notes.

The consensus estimates for the next quarter point to continued stable revenue growth for Quest Diagnostics, reflecting steady demand for diagnostic testing services in the United States, according to aggregate analyst figures from financial data platforms that track NYSE-listed healthcare companies. Earnings per share expectations also suggest a cautious but consistent margin profile, with several houses pointing to cost discipline and mix improvements as supporting factors in their recent commentary.

Upcoming earnings and calendar focus

In the week ahead, investors in Quest Diagnostics are focused on the company’s next earnings date, which typically falls in the regular quarterly reporting pattern for large S&P 500 constituents on the NYSE. The company’s investor relations calendar outlines the usual cadence of earnings releases and conference calls, giving investors clear dates when management will discuss recent performance and provide updates on testing volumes, reimbursement trends and strategic initiatives.

Quarterly earnings for Quest Diagnostics are a key reference point for the diagnostics sector, as the company reports on volumes in routine testing, advanced diagnostics and specialized assays across its US network of laboratories. These figures often provide context for broader healthcare spending and diagnostic utilization trends in the United States, and are closely watched by analysts covering healthcare services and equipment as part of their sector reports.

The business behind the stock

Quest Diagnostics generates its revenue primarily by providing diagnostic information services to physicians, hospitals and patients across the United States. The company operates a broad network of laboratories and patient service centers, offering routine blood tests, advanced molecular diagnostics and specialized pathology services as examples of its core offerings.

Where the stock trades today

The Quest Diagnostics shares (US74834L1008) trade on the New York Stock Exchange in US dollars. As of 2026-06-29, 09:45, the shares last changed hands at a level consistent with recent ranges observed for S&P 500 healthcare stocks, based on live exchange data.

Quest Diagnostics at a glance

• Company: Quest Diagnostics Inc.
• ISIN: US74834L1008
• WKN: 929416
• Ticker: DGX
• Trading venue: NYSE
• Price (as of 2026-06-29, 09:45): value USD
• Market cap: value USD (as of 2026-06-29)
• Sector / industry: Healthcare diagnostics and laboratory services
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not contain investment advice, personal recommendations or an offer to buy or sell securities. All data are based on sources believed to be reliable but cannot be guaranteed.